Cellerant Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Cellerant Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014394
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cellerant Therapeutics Inc (Cellerant) develops novel immunotherapies for oncology and blood-related disorders. Its lead product, CLT-008, is a myeloid progenitor cell therapy which is in Phase 2 clinical development in patients with acute myeloid leukemia (AML). Cellerant develops various cell therapy products and antibodies against malignant cells using its technology, hematopoietic stem cell biology. It also develops processes for autologous and allogeneic cell therapy manufacturing using its cell therapy process development technology. The company also provides cancer stem cell (CSC) antibody discovery program which focuses on therapies for acute myeloid leukemia (AML), multiple myeloma and myelodysplastic syndrome. Cellerant Therapeutics is headquartered in San Carlos, California, the US.

Cellerant Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Cellerant Therapeutics Raises USD2 Million in Venture Financing 10
Cellerant Therapeutics Raises US$1 Million In Venture Financing 11
Cellerant Therapeutics Raises US$0.9 Million In Venture Financing 12
Cellerant Therapeutics Secures US$0.8 Million In Financing 13
Partnerships 14
Cellerant Therapeutics Enters into Contract with National Institutes of Health 14
Cellerant Therapeutics Inc – Key Competitors 15
Cellerant Therapeutics Inc – Key Employees 16
Cellerant Therapeutics Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product News 18
09/26/2016: Cellerant Therapeutics Awarded $1.5 Million SBIR Contract for Development of Novel Antibody-Based Therapeutic Against IL1RAP 18
Clinical Trials 19
Aug 22, 2017: Cellerant Therapeutics Awarded $6.86 Million Grant From California Institute for Regenerative Medicine to Support Development of Novel Antibody-Drug Conjugate for AML 19
Oct 11, 2016: Cellerant Therapeutics Presents Preclinical Data Showing Promise of a Novel Differentiated Target on Leukemic Stem Cells 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cellerant Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Cellerant Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cellerant Therapeutics Raises USD2 Million in Venture Financing 10
Cellerant Therapeutics Raises US$1 Million In Venture Financing 11
Cellerant Therapeutics Raises US$0.9 Million In Venture Financing 12
Cellerant Therapeutics Secures US$0.8 Million In Financing 13
Cellerant Therapeutics Enters into Contract with National Institutes of Health 14
Cellerant Therapeutics Inc, Key Competitors 15
Cellerant Therapeutics Inc, Key Employees 16

★海外企業調査レポート[Cellerant Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Culture Landmark Investment Ltd
    Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report Summary Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Telecom Argentina S.A.
    Telecom Argentina S.A. - Strategy, SWOT and Corporate Finance Report Summary Telecom Argentina S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Saje Pharma LLC-製薬・医療分野:企業M&A・提携分析
    Summary Saje Pharma LLC (Saje Pharma) is a biopharmaceutical company that develops new therapeutic agents for rare and common diseases with unmet medical needs. The company’s lead product candidate includes SPL-334, developed for various indications such as idiopathic pulmonary fibrosis, asthma, inf …
  • Aixtron SE (AIXA):企業の財務・戦略的SWOT分析
    Aixtron SE (AIXA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Ascena Retail Group, Inc.:企業の戦略・SWOT・財務分析
    Ascena Retail Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ascena Retail Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Yamato Holdings Co., Ltd.:企業の戦略・SWOT・財務分析
    Yamato Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Yamato Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • CymaBay Therapeutics Inc (CBAY):製薬・医療:M&Aディール及び事業提携情報
    Summary CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, orphan diseases and related metabolic disorders. The company’s pipeline products comprise Arhalofenate, an oral small molecule intended for t …
  • DEA Deutsche Erdoel AG:石油・ガス:M&Aディール及び事業提携情報
    Summary DEA Deutsche Erdoel AG (DEA), a subsidiary of Letterone Holdings S.A., is an upstream company that explores for and produces oil and natural gas. The company operates onshore and offshore projects in Egyptian Nile delta, Mittelplate Island and Norwegian coast line and other regions. It also …
  • Dufry AG (DUFN):企業の財務・戦略的SWOT分析
    Dufry AG (DUFN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Bright Horizons Family Solutions LLC (BFAM):企業の財務・戦略的SWOT分析
    Summary Bright Horizons Family Solutions LLC (Bright Horizons) is a provider of educational advisory services and child care services. The company offers curriculum and programs including early education and preschool, back-up child and adult care programs, infant care, toddler care, college coach, …
  • BASF SE:企業の戦略・SWOT・財務情報
    BASF SE - Strategy, SWOT and Corporate Finance Report Summary BASF SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Swift Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Swift Biosciences Inc (Swift Biosciences) is a biotechnology company that develops novel research reagents, protocols, and molecular diagnostic tools. The company offers products such as 2S DNA library kit, 2S plus DNA library kit, 2S PCR-free DNA library kit, methyl-seq DNA library kit, DNA …
  • Zweites Deutsches Fernsehen:企業の戦略的SWOT分析
    Zweites Deutsches Fernsehen - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Exchange Income Corporation:企業の戦略・SWOT・財務分析
    Exchange Income Corporation - Strategy, SWOT and Corporate Finance Report Summary Exchange Income Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • NV Energy Inc-エネルギー分野:企業M&A・提携分析
    Summary NV Energy, Inc. (NVE), an indirect subsidiary of Berkshire Hathaway Energy Company, is an energy company, which provides a wide range of energy services and products through its principal subsidiaries, Nevada Power Company and Sierra Pacific Power Company. It delivers electricity to a large …
  • Fluxion Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Fluxion Biosciences Inc (Fluxion) is a provider of analytical and live cell analysis tools. The company’s products include IsoFlux system and CTC kits, BioFlux System, IonFlux System, Cytation CTC imager and enumeration kits, and sequencing kits. It provides analytical services for a range o …
  • Galera Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Galera Therapeutics Inc (Galera Therapeutics) is a clinical-stage biotechnology company that discovers and develops novel cancer treatments. The company also concentrates on the prevention of radiation-induced toxicity including mucositis and the treatment of cancer. Its GC4419 is a selectiv …
  • EnergySolutions LLC:企業の戦略的SWOT分析
    EnergySolutions LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • ANS Group Plc:企業の戦略的SWOT分析
    ANS Group Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Zynerba Pharmaceuticals Inc (ZYNE)-製薬・医療分野:企業M&A・提携分析
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz, Inc., focuses on the development of next-generation synthetic cannabinoid therapeutics. The company’s pipeline product candidates include ZYN002 and ZYN001. Zynerba’s ZYN002 is a synthetic CBD, a non-psychoactive canna …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆